• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by DaVita Inc.

    4/14/25 6:54:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    8-K
    false 0000927066 0000927066 2025-04-12 2025-04-12
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): April 12, 2025

     

     

    DAVITA INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    DE   1-14106   51-0354549

    (State or other jurisdiction

    of incorporation)

      (Commission
    File Number)
     

    (IRS Employer

    Identification No.)

     

    2000 16th Street
    Denver, CO 80202

    (Address of principal executive offices including Zip Code)

    (720) 631-2100

    (Registrant’s telephone number, including area code)

    Not applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:

     

    Trading
    symbol(s):

     

    Name of each exchange
    on which registered:

    Common Stock, $0.001 par value   DVA   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    ☐

    Emerging growth company

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01. Other Events.

    On April 12, 2025, DaVita Inc. (the “Company” or “we”) became aware of a ransomware incident that has encrypted certain elements of our network. Upon discovery, we activated our response protocols and implemented containment measures, including proactively isolating impacted systems. We are actively working to assess and remediate the incident with the assistance of third-party cybersecurity professionals and have notified law enforcement of the matter.

    We have implemented our contingency plans, and we continue to provide patient care. However, the incident is impacting some of our operations, and while we have implemented interim measures to allow for the restoration of certain functions, we cannot estimate the duration or extent of the disruption at this time.

    Given the recency of the incident, our investigation and response are ongoing, and the full scope, nature, and potential ultimate impact on the Company are not yet known.

    Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws and include, among other things, statements about the impact of this ransomware incident on the Company, the timeline on which operations impacted by the incident will be restored and the ultimate duration and extent of the disruption. All such statements in this report, other than statements of historical fact, are forward-looking statements. Words such as “expect,” “intend,” “will,” “plan,” “anticipate,” “may,” “believe,” “continue,” and similar expressions are intended to identify forward-looking statements. The Company bases its forward-looking statements on information available to it on the date of this report, and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may otherwise be required by law. Actual results and other events could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, the risk factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the other risks and uncertainties discussed in any subsequent reports that the Company files with the Securities and Exchange Commission from time to time.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      

    DAVITA INC.

    Date: April 14, 2025

      

    By:

      

    /s/ Kathleen A. Waters

          Kathleen A. Waters
          Chief Legal and Public Affairs Officer
    Get the next $DVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moore Gregory J. was granted 348 shares, increasing direct ownership by 6% to 6,451 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:15:16 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Berg Charles was granted 348 shares, increasing direct ownership by 2% to 19,982 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:15:04 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Yale Phyllis R was granted 348 shares, increasing direct ownership by 3% to 13,201 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:14:55 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    See more
    • DaVita Appoints Jessica Hergenreter as Chief People Officer

      DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

      10/17/24 1:00:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

      DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

      9/13/24 8:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints New Chief Information Officer

      Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

      5/13/24 9:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    SEC Filings

    See more
    • DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - DAVITA INC. (0000927066) (Filer)

      5/23/25 4:28:44 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - DAVITA INC. (0000927066) (Filer)

      5/20/25 4:58:28 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - DAVITA INC. (0000927066) (Filer)

      5/20/25 9:07:35 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

      DENVER, May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita. "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emph

      5/30/25 2:35:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship

      Captures key initiatives achieved in 2024, driving 2025 ESG goals DENVER, May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE:DVA) published its Community Care report, underpinning its long-standing commitment to corporate citizenship and highlighting strides made towards ambitious Environmental, Social and Governance (ESG) goals set to be achieved this year. Milestones and achievements reflect calendar year 2024. In 2021, DaVita announced broadened ESG goals and has since reported progress against its five strategic focus areas: Patient Care, Teammate Engagement, Environmental Stewardship, Healthy Communities and Leading with Integrity and Accountability. "This year, we're celebrating 25 years

      5/20/25 9:05:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 1st Quarter 2025 Results

      DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

      5/12/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DVA
    Financials

    Live finance-specific insights

    See more

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Barclays initiated coverage on DaVita with a new price target

      Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

      3/6/24 8:09:27 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita upgraded by UBS with a new price target

      UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

      8/7/23 7:20:56 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

      11/1/22 9:18:39 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 1st Quarter 2025 Results

      DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

      5/12/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

      DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the

      4/30/25 11:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 4th Quarter 2024 Results

      DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe

      2/13/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/13/24 5:02:42 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/9/22 3:43:35 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

      SC 13D/A - DAVITA INC. (0000927066) (Subject)

      8/4/21 4:02:59 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care